Article List
List all articles in the database by earliest discovery_date
GET /articles/?format=api&page=2442
{ "count": 24897, "next": "http://api.gregory-ms.com/articles/?format=api&page=2443", "previous": "http://api.gregory-ms.com/articles/?format=api&page=2441", "results": [ { "article_id": 488, "title": "QSM is an imaging biomarker for chronic glial activation in multiple sclerosis lesions", "summary": "<div><p>Ann Clin Transl Neurol. 2021 Mar 11. doi: 10.1002/acn3.51338. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">BACKGROUND: Inflammation in chronic active lesions occurs behind a closed blood-brain barrier and cannot be detected with MRI. Activated microglia are highly enriched for iron and can be visualized with quantitative susceptibility mapping (QSM), an MRI technique used to delineate iron.</p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">OBJECTIVE: To characterize the histopathological correlates of different QSM hyperintensity patterns in MS lesions.</p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">METHODS: MS brain slabs were imaged with MRI and QSM, and processed for histology. Immunolabeled cells were quantified in the lesion rim, center, and adjacent normal-appearing white matter (NAWM). Iron<sup>+</sup> myeloid cell densities at the rims were correlated with susceptibilities. Human-induced pluripotent stem cell (iPSC)-derived microglia were used to determine the effect of iron on the production of reactive oxygen species (ROS) and pro-inflammatory cytokines.</p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">RESULTS: QSM hyperintensity at the lesion perimeter correlated with activated iron<sup>+</sup> myeloid cells in the rim and NAWM. Lesions with high punctate or homogenous QSM signal contained no or minimally activated iron<sup>-</sup> myeloid cells. In vitro, iron accumulation was highest in M1-polarized human iPSC-derived microglia, but it did not enhance ROS or cytokine production.</p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">CONCLUSION: A high QSM signal outlining the lesion rim but not punctate signal in the center is a biomarker for chronic inflammation in white matter lesions.</p><p>PMID:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33704933/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210311230527&v=2.14.3\">33704933</a> | DOI:<a href=\"https://doi.org/10.1002/acn3.51338\">10.1002/acn3.51338</a></p></div>", "link": "https://pubmed.ncbi.nlm.nih.gov/33704933/#x3D;Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc&#x", "published_date": "2021-01-04T00:00:00Z", "sources": [ "PubMed" ], "teams": [ { "id": 1, "name": "Team Gregory" } ], "subjects": [ { "subject_name": "Multiple Sclerosis", "description": null } ], "publisher": "Wiley", "container_title": "Annals of Clinical and Translational Neurology", "authors": [ { "author_id": 183277, "given_name": "Kelly M.", "family_name": "Gillen", "ORCID": "http://orcid.org/0000-0003-1319-4900", "country": "US" }, { "author_id": 243861, "given_name": "Mayyan", "family_name": "Mubarak", "ORCID": null, "country": null }, { "author_id": 243862, "given_name": "Calvin", "family_name": "Park", "ORCID": null, "country": null }, { "author_id": 243863, "given_name": "Gerald", "family_name": "Ponath", "ORCID": null, "country": null }, { "author_id": 184171, "given_name": "Shun", "family_name": "Zhang", "ORCID": "http://orcid.org/0000-0002-0001-1880", "country": null }, { "author_id": 243864, "given_name": "Alexey", "family_name": "Dimov", "ORCID": null, "country": null }, { "author_id": 243865, "given_name": "Maya", "family_name": "Levine‐Ritterman", "ORCID": null, "country": null }, { "author_id": 243866, "given_name": "Steven", "family_name": "Toro", "ORCID": null, "country": null }, { "author_id": 243867, "given_name": "Weiyuan", "family_name": "Huang", "ORCID": null, "country": null }, { "author_id": 243868, "given_name": "Stephanie", "family_name": "Amici", "ORCID": null, "country": null }, { "author_id": 322788, "given_name": "Ulrike W.", "family_name": "Kaunzner", "ORCID": "http://orcid.org/0000-0001-9449-7369", "country": null }, { "author_id": 150183, "given_name": "Susan A.", "family_name": "Gauthier", "ORCID": "http://orcid.org/0000-0002-4015-1781", "country": null }, { "author_id": 243870, "given_name": "Mireia", "family_name": "Guerau‐de‐Arellano", "ORCID": null, "country": null }, { "author_id": 155850, "given_name": "Yi", "family_name": "Wang", "ORCID": "http://orcid.org/0000-0003-1404-8526", "country": "US" }, { "author_id": 243872, "given_name": "Thanh D.", "family_name": "Nguyen", "ORCID": null, "country": null }, { "author_id": 183278, "given_name": "David", "family_name": "Pitt", "ORCID": "http://orcid.org/0000-0002-6407-9542", "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2021-03-12T04:05:29Z", "noun_phrases": [ "QSM", "an imaging biomarker", "chronic glial activation", "multiple sclerosis lesions" ], "doi": "10.1002/acn3.51338", "access": "open", "takeaways": " Inflammation in chronic active lesions occurs behind a closed blood-brain barrier and cannot be detected with MRI . Activated microglia are highly enriched for iron and can be visualized with quantitative susceptibility mapping . Iron+ myeloid cell densities at the rims were correlated with susceptibilities .", "categories": [] }, { "article_id": 487, "title": "The perceived impact of multiple sclerosis and self-management: The mediating role of coping strategies", "summary": "<div><p>PLoS One. 2021 Mar 11;16(3):e0248135. doi: 10.1371/journal.pone.0248135. eCollection 2021.</p><p><b>ABSTRACT</b></p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">Low level of self-management in people with multiple sclerosis (MS) is considered to be a predominant factor that leads to poor rehabilitation efficacy. Studies focusing on the relationship between self-management and psychological variables that can be modified could contribute to expanding the knowledge needed to propose interventional programs aiming at patient activation. This study aimed to analyze whether coping strategies play a mediating role in the association between the perceived impact of MS and level of self-management in people with MS. The cross-sectional study included 382 people with MS. The participants completed the Multiple Sclerosis Self-Management Scale-Revised, Multiple Sclerosis Impact Scale-29, and Coping Inventory for Stressful Situations. The study hypothesis was evaluated using mediation analysis. The STROBE checklist specifically prepared for cross-sectional research was applied in this study for reporting. Results indicate that the emotion- and problem-focused strategies of coping can be treated as mediating the association between the MS impact and level of self-management in people with MS. A negative relationship was found between the perceived MS impact and problem-oriented coping, while a positive relationship was found between problem-oriented coping and self-management. Furthermore, a positive relationship was found between the MS impact and emotion-oriented coping, while a negative relationship was found between emotion-oriented coping and self-management. The indirect role of avoidance-oriented coping was not significant. Our study confirms the role played by coping strategies in individuals' self-management. In MS, self-management determined by perceived MS impact can be controlled by decreasing emotional-coping while increasing problem-coping strategies. Our study imparts new knowledge regarding the potential interventions for improving the level of self-management in people with MS. It indicates that recognition of individuals' illness perceptions as well as maladaptive coping strategies can help health professionals identify those who might be having lower level of self-management.</p><p>PMID:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33705470/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210311230527&v=2.14.3\">33705470</a> | DOI:<a href=\"https://doi.org/10.1371/journal.pone.0248135\">10.1371/journal.pone.0248135</a></p></div>", "link": "https://pubmed.ncbi.nlm.nih.gov/33705470/#x3D;Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc&#x", "published_date": "2021-03-11T00:00:00Z", "sources": [ "PubMed" ], "teams": [ { "id": 1, "name": "Team Gregory" } ], "subjects": [ { "subject_name": "Multiple Sclerosis", "description": null } ], "publisher": "Public Library of Science (PLoS)", "container_title": "PLOS ONE", "authors": [ { "author_id": 156878, "given_name": "Maciej", "family_name": "Wilski", "ORCID": "http://orcid.org/0000-0003-4856-3016", "country": "PL" }, { "author_id": 156879, "given_name": "Waldemar", "family_name": "Brola", "ORCID": "http://orcid.org/0000-0002-7955-3454", "country": null }, { "author_id": 156880, "given_name": "Magdalena", "family_name": "Łuniewska", "ORCID": "http://orcid.org/0000-0002-8168-4744", "country": null }, { "author_id": 243906, "given_name": "Maciej", "family_name": "Tomczak", "ORCID": null, "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2021-03-12T04:05:29Z", "noun_phrases": [ "The perceived impact", "multiple sclerosis", "self-management", "The mediating role", "strategies" ], "doi": "10.1371/journal.pone.0248135", "access": "open", "takeaways": " Low level of self-management in people with MS is considered to be a predominant factor that leads to poor rehabilitation efficacy .", "categories": [] }, { "article_id": 490, "title": "MS is rare in EBV-seronegative children with CNS inflammatory demyelination", "summary": "<div><p>Ann Neurol. 2021 Mar 11. doi: 10.1002/ana.26062. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">Although Epstein-Barr virus (EBV) is hypothesized to be a prerequisite for multiple sclerosis (MS), up to 15% of children with a diagnosis of MS were reported to be EBV-seronegative. When re-evaluating 25 EBV-seronegative children out of 189 pediatric patients with a diagnosis of clinically isolated syndrome/MS, we found anti-myelin oligodendrocyte glycoprotein (MOG) antibody in 11/25 (44%) EBV-seronegative, but only 9/164 (5.5%, p < 0.001) EBV-seropositive patients. After critical review, MS remained a plausible diagnosis in only four of 14 EBV-seronegative/MOG antibody-negative patients. In children with an MS-like presentation, EBV seronegativity should alert clinicians to consider diagnoses other than MS, especially MOG-antibody disease. This article is protected by copyright. All rights reserved.</p><p>PMID:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33704815/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210311230527&v=2.14.3\">33704815</a> | DOI:<a href=\"https://doi.org/10.1002/ana.26062\">10.1002/ana.26062</a></p></div>", "link": "https://pubmed.ncbi.nlm.nih.gov/33704815/#x3D;Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc&#x", "published_date": "2021-01-06T00:00:00Z", "sources": [ "PubMed" ], "teams": [ { "id": 1, "name": "Team Gregory" } ], "subjects": [ { "subject_name": "Multiple Sclerosis", "description": null } ], "publisher": "Wiley", "container_title": "Annals of Neurology", "authors": [ { "author_id": 171980, "given_name": "Bardia", "family_name": "Nourbakhsh", "ORCID": "http://orcid.org/0000-0002-6617-2003", "country": null }, { "author_id": 152815, "given_name": "Christian", "family_name": "Cordano", "ORCID": "http://orcid.org/0000-0002-1413-0442", "country": "IT" }, { "author_id": 222748, "given_name": "Carlo", "family_name": "Asteggiano", "ORCID": "http://orcid.org/0000-0002-1439-3293", "country": null }, { "author_id": 156906, "given_name": "Klemens", "family_name": "Ruprecht", "ORCID": "http://orcid.org/0000-0003-1962-6014", "country": null }, { "author_id": 243895, "given_name": "Carolin", "family_name": "Otto", "ORCID": null, "country": null }, { "author_id": 318694, "given_name": "Alice", "family_name": "Rutatangwa", "ORCID": "http://orcid.org/0000-0003-0843-7947", "country": null }, { "author_id": 243899, "given_name": "Allysa", "family_name": "Lui", "ORCID": null, "country": null }, { "author_id": 243900, "given_name": "Janace", "family_name": "Hart", "ORCID": null, "country": null }, { "author_id": 243901, "given_name": "Eoin P.", "family_name": "Flanagan", "ORCID": null, "country": null }, { "author_id": 243902, "given_name": "Judith A.", "family_name": "James", "ORCID": null, "country": null }, { "author_id": 151879, "given_name": "Emmanuelle", "family_name": "Waubant", "ORCID": "http://orcid.org/0000-0001-5188-0157", "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2021-03-12T04:05:29Z", "noun_phrases": [ "MS", "EBV-seronegative children", "CNS inflammatory demyelination" ], "doi": "10.1002/ana.26062", "access": "open", "takeaways": " Epstein-Barr virus is hypothesized to be a prerequisite for multiple sclerosis . Up to 15% of children with a diagnosis of MS were reported to be EBV-seropositive . Anti-myelin oligodendrocyte glycoprotein (MOG) antibody in 11", "categories": [ { "category_id": 46, "category_description": "Epstein-Barr virus (EBV), also known as human herpesvirus 4, is a member of the herpes virus family. It is one of the most common human viruses. EBV is found all over the world. Most people get infected with EBV at some point in their lives. EBV spreads most commonly through bodily fluids, primarily saliva. EBV can cause infectious mononucleosis, also called mono, and other illnesses.\r\n\r\nsource: <a href=\"https://www.cdc.gov/epstein-barr/about-ebv.html\">https://www.cdc.gov/epstein-barr/about-ebv.html</a>\r\n\r\nEBV may be a leading cause of multiple sclerosis. \r\nsource: <a href=\"https://www.nature.com/articles/s41582-023-00775-5\">https://www.nature.com/articles/s41582-023-00775-5</a>", "category_name": "Epstein-Barr Virus", "category_slug": "epstein-barr-virus", "category_terms": [ "ebv", "Epstein-Barr" ], "article_count": 163 } ] }, { "article_id": 489, "title": "Evaluation of Pharmacokinetics, Safety, and Drug-Drug Interactions of an Oral Suspension of Edaravone in Healthy Adults", "summary": "<div><p>Clin Pharmacol Drug Dev. 2021 Mar 11. doi: 10.1002/cpdd.925. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">Intravenous (IV) edaravone is approved as an amyotrophic lateral sclerosis (ALS) treatment. Because IV administration places a burden on patients, development of orally administered ALS treatments is needed. Therefore, 2 phase 1 studies of oral formulations of edaravone in healthy subjects examined the pharmacokinetics (PK), safety, racial differences, and drug-drug interactions (DDIs) and investigated the dose of the oral formulation considered to be bioequivalent to the approved dose of the IV formulation. Study 1 was a placebo-controlled, randomized, single-blind study of single-ascending-dose oral edaravone with the dose range of 30 to 300 mg (n = 56). Study 2 was conducted in 2 cohorts (n = 84); the first assessed DDIs with multiple-dose edaravone 120 mg/day given over 5 or 8 days (coadministered with single-dose rosuvastatin, sildenafil, or furosemide), and the second evaluated PK and racial (Japanese/White) differences in PK parameters with doses of 100-mg edaravone. The oral formulation of edaravone was well absorbed, and plasma concentrations of unchanged edaravone increased more than dose proportionally within the dose range of 30 to 300 mg. No effect of race on oral edaravone PK and no notable DDI effects possibly caused by orally administered edaravone were observed. The oral edaravone formulations were safe and tolerable under the assessed conditions. Mathematical modeling determined that equivalent exposures in plasma with the approved dose of the IV edaravone formulation, as reported previously, could be achieved when the oral edaravone formulation was administered at a dose of ≈100 mg, with an absolute bioavailability of ≈60%.</p><p>PMID:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33704925/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210311230527&v=2.14.3\">33704925</a> | DOI:<a href=\"https://doi.org/10.1002/cpdd.925\">10.1002/cpdd.925</a></p></div>", "link": "https://pubmed.ncbi.nlm.nih.gov/33704925/#x3D;Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc&#x", "published_date": "2021-01-10T00:00:00Z", "sources": [ "PubMed" ], "teams": [ { "id": 1, "name": "Team Gregory" } ], "subjects": [ { "subject_name": "Multiple Sclerosis", "description": null } ], "publisher": "Wiley", "container_title": "Clinical Pharmacology in Drug Development", "authors": [ { "author_id": 243883, "given_name": "Hidetoshi", "family_name": "Shimizu", "ORCID": null, "country": null }, { "author_id": 243884, "given_name": "Yukiko", "family_name": "Nishimura", "ORCID": null, "country": null }, { "author_id": 243885, "given_name": "Yoichi", "family_name": "Shiide", "ORCID": null, "country": null }, { "author_id": 243886, "given_name": "Hideaki", "family_name": "Matsuda", "ORCID": null, "country": null }, { "author_id": 243887, "given_name": "Makoto", "family_name": "Akimoto", "ORCID": null, "country": null }, { "author_id": 243889, "given_name": "Munetomo", "family_name": "Matsuda", "ORCID": null, "country": null }, { "author_id": 243891, "given_name": "Yoshinobu", "family_name": "Nakamaru", "ORCID": null, "country": null }, { "author_id": 243892, "given_name": "Yuichiro", "family_name": "Kato", "ORCID": null, "country": null }, { "author_id": 243893, "given_name": "Kazuoki", "family_name": "Kondo", "ORCID": null, "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2021-03-12T04:05:29Z", "noun_phrases": [ "Evaluation", "Pharmacokinetics", "Safety", "Drug-Drug Interactions", "an Oral Suspension", "Edaravone", "Healthy Adults" ], "doi": "10.1002/cpdd.925", "access": "open", "takeaways": " Intravenous (IV) edaravone is approved as an amyotrophic lateral sclerosis (ALS) treatment . Study 1 was a placebo-controlled, randomized, single-blind study . Study 2 was conducted in 2 cohorts (n = 84) of healthy subjects .", "categories": [] }, { "article_id": 491, "title": "Correction to: Validity of the Italian multiple sclerosis neuropsychological screening questionnaire", "summary": "<div><p>Neurol Sci. 2021 Mar 11. doi: 10.1007/s10072-021-05168-4. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p>PMID:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33704600/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210311230527&v=2.14.3\">33704600</a> | DOI:<a href=\"https://doi.org/10.1007/s10072-021-05168-4\">10.1007/s10072-021-05168-4</a></p></div>", "link": "https://pubmed.ncbi.nlm.nih.gov/33704600/#x3D;Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc&#x", "published_date": "2021-01-11T00:00:00Z", "sources": [ "PubMed" ], "teams": [ { "id": 1, "name": "Team Gregory" } ], "subjects": [ { "subject_name": "Multiple Sclerosis", "description": null } ], "publisher": "Springer Science and Business Media LLC", "container_title": "Neurological Sciences", "authors": [ { "author_id": 221823, "given_name": "Simone", "family_name": "Migliore", "ORCID": "http://orcid.org/0000-0002-2665-231X", "country": null }, { "author_id": 244543, "given_name": "Doriana", "family_name": "Landi", "ORCID": null, "country": null }, { "author_id": 297371, "given_name": "Francesca", "family_name": "Proietti", "ORCID": null, "country": null }, { "author_id": 300978, "given_name": "Giulia", "family_name": "D’Aurizio", "ORCID": null, "country": null }, { "author_id": 300979, "given_name": "Ferdinando", "family_name": "Squitieri", "ORCID": null, "country": null }, { "author_id": 246761, "given_name": "Giorgia", "family_name": "Mataluni", "ORCID": null, "country": null }, { "author_id": 244567, "given_name": "Carolina Gabri", "family_name": "Nicoletti", "ORCID": null, "country": null }, { "author_id": 297372, "given_name": "Giuseppe", "family_name": "Curcio", "ORCID": null, "country": null }, { "author_id": 207541, "given_name": "Girolama Alessandra", "family_name": "Marfia", "ORCID": "http://orcid.org/0000-0001-5863-7758", "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2021-03-12T04:05:29Z", "noun_phrases": [ "Correction to: Validity", "the Italian multiple sclerosis", "neuropsychological screening questionnaire" ], "doi": "10.1007/s10072-021-05168-4", "access": "open", "takeaways": "", "categories": [] }, { "article_id": 494, "title": "Structural Basis of Tirasemtiv Activation of Fast Skeletal Muscle", "summary": "<div><p>J Med Chem. 2021 Mar 11. doi: 10.1021/acs.jmedchem.0c01412. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">Troponin regulates the calcium-mediated activation of skeletal muscle. Muscle weakness in diseases such as amyotrophic lateral sclerosis and spinal muscular atrophy occurs from diminished neuromuscular output. The first direct fast skeletal troponin activator, <i>tirasemtiv</i>, amplifies the response of muscle to neuromuscular input. <i>Tirasemtiv</i> binds selectively and strongly to fast skeletal troponin, slowing the rate of calcium release and sensitizing muscle to calcium. We report the solution NMR structure of <i>tirasemtiv</i> bound to a fast skeletal troponin C-troponin I chimera. The structure reveals that <i>tirasemtiv</i> binds in a hydrophobic pocket between the regulatory domain of troponin C and the switch region of troponin I, which overlaps with that of Anapoe in the X-ray structure of skeletal troponin. Multiple interactions stabilize the troponin C-troponin I interface, increase the affinity of troponin C for the switch region of fast skeletal troponin I, and drive the equilibrium toward the active state.</p><p>PMID:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33703886/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210311230527&v=2.14.3\">33703886</a> | DOI:<a href=\"https://doi.org/10.1021/acs.jmedchem.0c01412\">10.1021/acs.jmedchem.0c01412</a></p></div>", "link": "https://pubmed.ncbi.nlm.nih.gov/33703886/#x3D;Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc&#x", "published_date": "2021-03-25T00:00:00Z", "sources": [ "PubMed" ], "teams": [ { "id": 1, "name": "Team Gregory" } ], "subjects": [ { "subject_name": "Multiple Sclerosis", "description": null } ], "publisher": "American Chemical Society (ACS)", "container_title": "Journal of Medicinal Chemistry", "authors": [ { "author_id": 295263, "given_name": "Monica X.", "family_name": "Li", "ORCID": null, "country": null }, { "author_id": 295264, "given_name": "Pascal", "family_name": "Mercier", "ORCID": null, "country": null }, { "author_id": 295265, "given_name": "James J.", "family_name": "Hartman", "ORCID": null, "country": null }, { "author_id": 199567, "given_name": "Brian D.", "family_name": "Sykes", "ORCID": "http://orcid.org/0000-0003-2544-2246", "country": "CA" } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2021-03-12T04:05:29Z", "noun_phrases": [ "Structural Basis", "Tirasemtiv Activation", "Fast Skeletal Muscle" ], "doi": "10.1021/acs.jmedchem.0c01412", "access": "restricted", "takeaways": " The first direct fast skeletal troponin activator, tirasemtiv, amplifies the response of muscle to neuromuscular input .", "categories": [] }, { "article_id": 485, "title": "Altered communication dynamics reflect cognitive deficits in temporal lobe epilepsy", "summary": "<div><p>Epilepsia. 2021 Mar 11. doi: 10.1111/epi.16864. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">OBJECTIVE: Although temporal lobe epilepsy (TLE) is recognized as a system-level disorder, little work has investigated pathoconnectomics from a dynamic perspective. By leveraging computational simulations that quantify patterns of information flow across the connectome, we tested the hypothesis that network communication is abnormal in this condition, studied the interplay between hippocampal- and network-level disease effects, and assessed associations with cognition.</p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">METHODS: We simulated signal spreading via a linear threshold model that temporally evolves on a structural graph derived from diffusion-weighted magnetic resonance imaging (MRI), comparing a homogeneous group of 31 patients with histologically proven hippocampal sclerosis to 31 age- and sex-matched healthy controls. We evaluated the modulatory effects of structural alterations of the neocortex and hippocampus on network dynamics. Furthermore, multivariate statistics addressed the relationship with cognitive parameters.</p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">RESULTS: We observed a slowing of in- and out-spreading times across multiple areas bilaterally, indexing delayed information flow, with the strongest effects in ipsilateral frontotemporal regions, thalamus, and hippocampus. Effects were markedly reduced when controlling for hippocampal volume but not cortical thickness, underscoring the central role of the hippocampus in whole-brain disease expression. Multivariate analysis associated slower spreading time in frontoparietal, limbic, default mode, and subcortical networks with impairment across tasks tapping into sensorimotor, executive, memory, and verbal abilities.</p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">SIGNIFICANCE: Moving beyond descriptions of static topology toward the formulation of brain dynamics, our work provides novel insight into structurally mediated network dysfunction and demonstrates that altered whole-brain communication dynamics contribute to common cognitive difficulties in TLE.</p><p>PMID:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33705572/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210311230527&v=2.14.3\">33705572</a> | DOI:<a href=\"https://doi.org/10.1111/epi.16864\">10.1111/epi.16864</a></p></div>", "link": "https://pubmed.ncbi.nlm.nih.gov/33705572/#x3D;Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc&#x", "published_date": "2021-01-04T00:00:00Z", "sources": [ "PubMed" ], "teams": [ { "id": 1, "name": "Team Gregory" } ], "subjects": [ { "subject_name": "Multiple Sclerosis", "description": null } ], "publisher": "Wiley", "container_title": "Epilepsia", "authors": [ { "author_id": 185436, "given_name": "Mauricio", "family_name": "Girardi‐Schappo", "ORCID": "http://orcid.org/0000-0002-9111-4905", "country": "BR" }, { "author_id": 285192, "given_name": "Fatemeh", "family_name": "Fadaie", "ORCID": null, "country": null }, { "author_id": 285193, "given_name": "Hyo Min", "family_name": "Lee", "ORCID": null, "country": null }, { "author_id": 285194, "given_name": "Benoit", "family_name": "Caldairou", "ORCID": null, "country": null }, { "author_id": 285195, "given_name": "Viviane", "family_name": "Sziklas", "ORCID": null, "country": null }, { "author_id": 285196, "given_name": "Joelle", "family_name": "Crane", "ORCID": null, "country": null }, { "author_id": 185442, "given_name": "Boris C.", "family_name": "Bernhardt", "ORCID": "http://orcid.org/0000-0001-9256-6041", "country": null }, { "author_id": 185443, "given_name": "Andrea", "family_name": "Bernasconi", "ORCID": "http://orcid.org/0000-0001-9358-5703", "country": null }, { "author_id": 185444, "given_name": "Neda", "family_name": "Bernasconi", "ORCID": "http://orcid.org/0000-0002-8947-9518", "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2021-03-12T04:05:29Z", "noun_phrases": [ "Altered communication dynamics", "cognitive deficits", "temporal lobe epilepsy" ], "doi": "10.1111/epi.16864", "access": "restricted", "takeaways": " Little work has investigated pathoconnectomics from a dynamic perspective . We simulated signal spreading via a linear threshold model that temporally evolves on a structural graph . We evaluated the modulatory effects of structural alterations of the neocortex and hippocampus on network dynamics .", "categories": [] }, { "article_id": 484, "title": "UK prevalence of underlying conditions which increase the risk of severe COVID-19 disease: a point prevalence study using electronic health records", "summary": "Background: Characterising the size and distribution of the population at risk of severe COVID-19 is vital for effective policy and planning. Older age, and underlying health conditions, are associated with higher risk of death from COVID-19. This study aimed to describe the population at risk of severe COVID-19 due to underlying health conditions across the United Kingdom.MethodsWe used anonymised electronic health records from the Clinical Practice Research Datalink GOLD to estimate the point prevalence on 5 March 2019 of the at-risk population following national guidance. Prevalence for any risk condition and for each individual condition is given overall and stratified by age and region with binomial exact confidence intervals. We repeated the analysis on 5 March 2014 for full regional representation and to describe prevalence of underlying health conditions in pregnancy. We additionally described the population of cancer survivors, and assessed the value of linked secondary care records for ascertaining COVID-19 at-risk status.ResultsOn 5 March 2019, 24.4% of the UK population were at risk due to a record of at least one underlying health condition, including 8.3% of school-aged children, 19.6% of working-aged adults, and 66.2% of individuals aged 70 years or more. 7.1% of the population had multimorbidity. The size of the at-risk population was stable over time comparing 2014 to 2019, despite increases in chronic liver disease and diabetes and decreases in chronic kidney disease and current asthma. Separately, 1.6% of the population had a new diagnosis of cancer in the past 5 y.ConclusionsThe population at risk of severe COVID-19 (defined as either aged ≥70 years, or younger with an underlying health condition) comprises 18.5 million individuals in the UK, including a considerable proportion of school-aged and working-aged individuals. Our national estimates broadly support the use of Global Burden of Disease modelled estimates in other countries. We provide age- and region- stratified prevalence for each condition to support effective modelling of public health interventions and planning of vaccine resource allocation. The high prevalence of health conditions among older age groups suggests that age-targeted vaccination strategies may efficiently target individuals at higher risk of severe COVID-19.", "link": "https://bmcpublichealth.biomedcentral.com/articles/10.1186/s12889-021-10427-2", "published_date": "2021-03-11T00:00:00Z", "sources": [ "BioMedCentral" ], "teams": [ { "id": 1, "name": "Team Gregory" } ], "subjects": [ { "subject_name": "Multiple Sclerosis", "description": null } ], "publisher": "Springer Science and Business Media LLC", "container_title": "BMC Public Health", "authors": [ { "author_id": 243840, "given_name": "Jemma L.", "family_name": "Walker", "ORCID": null, "country": null }, { "author_id": 243841, "given_name": "Daniel J.", "family_name": "Grint", "ORCID": null, "country": null }, { "author_id": 243842, "given_name": "Helen", "family_name": "Strongman", "ORCID": null, "country": null }, { "author_id": 243843, "given_name": "Rosalind M.", "family_name": "Eggo", "ORCID": null, "country": null }, { "author_id": 243844, "given_name": "Maria", "family_name": "Peppa", "ORCID": null, "country": null }, { "author_id": 243845, "given_name": "Caroline", "family_name": "Minassian", "ORCID": null, "country": null }, { "author_id": 243846, "given_name": "Kathryn E.", "family_name": "Mansfield", "ORCID": null, "country": null }, { "author_id": 243847, "given_name": "Christopher T.", "family_name": "Rentsch", "ORCID": null, "country": null }, { "author_id": 243848, "given_name": "Ian J.", "family_name": "Douglas", "ORCID": null, "country": null }, { "author_id": 243849, "given_name": "Rohini", "family_name": "Mathur", "ORCID": null, "country": null }, { "author_id": 243850, "given_name": "Angel Y. S.", "family_name": "Wong", "ORCID": null, "country": null }, { "author_id": 243851, "given_name": "Jennifer K.", "family_name": "Quint", "ORCID": null, "country": null }, { "author_id": 243852, "given_name": "Nick", "family_name": "Andrews", "ORCID": null, "country": null }, { "author_id": 243853, "given_name": "Jamie Lopez", "family_name": "Bernal", "ORCID": null, "country": null }, { "author_id": 243854, "given_name": "J. Anthony", "family_name": "Scott", "ORCID": null, "country": null }, { "author_id": 243855, "given_name": "Mary", "family_name": "Ramsay", "ORCID": null, "country": null }, { "author_id": 243856, "given_name": "Liam", "family_name": "Smeeth", "ORCID": null, "country": null }, { "author_id": 207139, "given_name": "Helen I.", "family_name": "McDonald", "ORCID": "http://orcid.org/0000-0003-0576-2015", "country": null } ], "relevant": false, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2021-03-12T00:25:58Z", "noun_phrases": [ "UK prevalence", "underlying conditions", "which", "the risk", "severe COVID-19 disease", "a point prevalence study", "electronic health records" ], "doi": "10.1186/s12889-021-10427-2", "access": "open", "takeaways": " The population at risk of severe COVID-19 comprises 18.5 million individuals in the UK, including school-aged and working-aged individuals . The high prevalence of health conditions among older age groups suggests age-targeted vaccination strategies may efficiently target individuals at higher risk .", "categories": [] }, { "article_id": 479, "title": "Formation and immunomodulatory function of meningeal B-cell aggregates in progressive CNS autoimmunity", "summary": "<div><p>Brain. 2021 Mar 9:awab093. doi: 10.1093/brain/awab093. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">Meningeal B lymphocyte aggregates have been described in autopsy material of patients with chronic Multiple Sclerosis. The presence of meningeal B cell aggregates has been correlated with worse disease. However, the functional role of these meningeal B cell aggregates is not understood. Here, we use a mouse model of Multiple Sclerosis, the spontaneous opticospinal encephalomyelitis model, which is built on the double transgenic expression of myelin oligodendrocyte glycoprotein-specific T cell- and B cell-receptors, to show that the formation of meningeal B cell aggregates is dependent on the expression of α4 integrins by antigen-specific T cells. T cell-conditional genetic ablation of α4 integrins in opticospinal encephalomyelitis mice impaired the formation of meningeal B cell aggregates, and surprisingly, led to a higher disease incidence as compared to opticospinal encephalomyelitis mice with α4 integrin-sufficient T cells. B cell-conditional ablation of α4 integrins in opticospinal encephalomyelitis mice resulted in the entire abrogation of the formation of meningeal B cell aggregates, and opticospinal encephalomyelitis mice with α4 integrin-deficient B cells suffered from a higher disease burden than regular opticospinal encephalomyelitis mice. While anti-CD20 antibody-mediated systemic depletion of B cells in opticospinal encephalomyelitis mice after onset of disease failed to efficiently decrease meningeal B cell aggregates without significantly modulating disease progression, treatment with anti-CD19 chimeric antigen receptor-T cells eliminated meningeal B cell aggregates and exacerbated clinical disease in opticospinal encephalomyelitis mice. Since about 20 percent of B cells in organised meningeal B cell aggregates produced either IL-10 or IL-35, we propose that meningeal B cell aggregates might also have an immunoregulatory function as to the immunopathology in adjacent spinal cord white matter. The immunoregulatory function of meningeal B cell aggregates needs to be considered when designing highly efficient therapies directed against meningeal B cell aggregates for clinical application in Multiple Sclerosis.</p><p>PMID:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33693558/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210311134527&v=2.14.2\">33693558</a> | DOI:<a href=\"https://doi.org/10.1093/brain/awab093\">10.1093/brain/awab093</a></p></div>", "link": "https://pubmed.ncbi.nlm.nih.gov/33693558/#x3D;Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc&#x", "published_date": "2021-07-27T23:00:00Z", "sources": [ "PubMed" ], "teams": [ { "id": 1, "name": "Team Gregory" } ], "subjects": [ { "subject_name": "Multiple Sclerosis", "description": null } ], "publisher": "Oxford University Press (OUP)", "container_title": "Brain", "authors": [ { "author_id": 243773, "given_name": "Meike", "family_name": "Mitsdoerffer", "ORCID": null, "country": null }, { "author_id": 195680, "given_name": "Giovanni", "family_name": "Di Liberto", "ORCID": "http://orcid.org/0000-0001-6788-0215", "country": null }, { "author_id": 243774, "given_name": "Sarah", "family_name": "Dötsch", "ORCID": null, "country": null }, { "author_id": 179237, "given_name": "Christopher", "family_name": "Sie", "ORCID": "http://orcid.org/0000-0002-8066-7539", "country": null }, { "author_id": 157965, "given_name": "Ingrid", "family_name": "Wagner", "ORCID": "http://orcid.org/0000-0003-4437-9799", "country": null }, { "author_id": 243775, "given_name": "Monika", "family_name": "Pfaller", "ORCID": null, "country": null }, { "author_id": 157966, "given_name": "Mario", "family_name": "Kreutzfeldt", "ORCID": "http://orcid.org/0000-0003-0335-2733", "country": null }, { "author_id": 243776, "given_name": "Simon", "family_name": "Fräßle", "ORCID": null, "country": null }, { "author_id": 199739, "given_name": "Lilian", "family_name": "Aly", "ORCID": "http://orcid.org/0000-0002-7051-124X", "country": "DE" }, { "author_id": 150324, "given_name": "Benjamin", "family_name": "Knier", "ORCID": "http://orcid.org/0000-0003-4187-9472", "country": "DE" }, { "author_id": 243777, "given_name": "Dirk H", "family_name": "Busch", "ORCID": null, "country": null }, { "author_id": 195688, "given_name": "Doron", "family_name": "Merkler", "ORCID": "http://orcid.org/0000-0002-0247-2007", "country": null }, { "author_id": 150325, "given_name": "Thomas", "family_name": "Korn", "ORCID": "http://orcid.org/0000-0002-3633-0955", "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2021-03-11T18:45:29Z", "noun_phrases": [ "Formation and immunomodulatory function", "meningeal B-cell aggregates", "progressive CNS autoimmunity" ], "doi": "10.1093/brain/awab093", "access": "open", "takeaways": " Meningeal B lymphocyte aggregates have been described in autopsy material of patients with chronic Multiple Sclerosis . We propose that meningeal B cell aggregates might also have an immunoregulatory function as to immunopathology in adjacent spinal cord white matter .", "categories": [] }, { "article_id": 476, "title": "Insights for Fostering Resilience in Young Adults With Multiple Sclerosis in the Aftermath of the COVID-19 Emergency: An Italian Survey", "summary": "<div><p>Front Psychiatry. 2021 Feb 22;11:588275. doi: 10.3389/fpsyt.2020.588275. eCollection 2020.</p><p><b>ABSTRACT</b></p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\"><b>Objective:</b> Recent evidence has demonstrated that the COVID-19 pandemic is taking a toll on the mental health of the general population. The psychological consequences might be even more severe for patients with special healthcare needs and psychological vulnerabilities due to chronic diseases, such as multiple sclerosis (MS). Thus, we aimed to explore the psychological impact of this pandemic and of the subsequent healthcare service changes on young adults with MS living in Italy and to examine their coping strategies and preferences regarding psychological support in the aftermath of the pandemic. <b>Methods:</b> Data were collected using a cross-sectional, web-based survey advertised on social networks. We report both quantitative (descriptive statistics, <i>t</i>-tests, and one-way ANOVA) and qualitative data (inductive content analysis). <b>Results:</b> Two hundred and forty-seven respondents (mean age 32 ± 7 years), mainly with relapsing-remitting MS, from all Italian regions participated. Participants felt more worried, confused, sad, and vulnerable because of the disease \"during\" the pandemic in comparison to their self-evaluation of the period \"before\" the COVID-19 outbreak. Similarly, their perception of control over MS decreased \"during\" the pandemic in comparison to the retrospective evaluation of the period \"before\" the COVID-19 outbreak (<i>p</i> < 0.01). Canceled/postponed visits/exams were listed as the most frequent MS management changes, with modified/postponed pharmacological treatment representing the most stressful change. Psychological support in dealing with pandemic-related fears and improving MS acceptance and well-being was considered extremely important by almost 40% of the respondents. Different coping strategies were mentioned in the qualitative section of the survey, with social support, hobbies, and keeping busy being the most frequent ones. <b>Conclusions:</b> Considering the enormous impact of the pandemic on young adults with MS, we urge MS clinical centers to implement psychological support programs that address the potentially long-lasting psychological negative impact, thus fostering the therapeutic alliance that is being threatened by the infection prevention measures imposed during the pandemic, and promoting psychological resources for adaptively managing future waves of COVID-19.</p><p>PMID:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33692703/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210311134527&v=2.14.2\">33692703</a> | PMC:<a href=\"https://www.ncbi.nlm.nih.gov/pmc/PMC7938709/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210311134527&v=2.14.2\">PMC7938709</a> | DOI:<a href=\"https://doi.org/10.3389/fpsyt.2020.588275\">10.3389/fpsyt.2020.588275</a></p></div>", "link": "https://pubmed.ncbi.nlm.nih.gov/33692703/#x3D;Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc&#x", "published_date": "2021-02-22T00:00:00Z", "sources": [ "PubMed" ], "teams": [ { "id": 1, "name": "Team Gregory" } ], "subjects": [ { "subject_name": "Multiple Sclerosis", "description": null } ], "publisher": "Frontiers Media SA", "container_title": "Frontiers in Psychiatry", "authors": [ { "author_id": 243797, "given_name": "Valeria", "family_name": "Donisi", "ORCID": null, "country": null }, { "author_id": 167447, "given_name": "Alberto", "family_name": "Gajofatto", "ORCID": "http://orcid.org/0000-0001-6539-0458", "country": null }, { "author_id": 243798, "given_name": "Maria Angela", "family_name": "Mazzi", "ORCID": null, "country": null }, { "author_id": 243799, "given_name": "Francesca", "family_name": "Gobbin", "ORCID": null, "country": null }, { "author_id": 243800, "given_name": "Isolde Martina", "family_name": "Busch", "ORCID": null, "country": null }, { "author_id": 243801, "given_name": "Annamaria", "family_name": "Ghellere", "ORCID": null, "country": null }, { "author_id": 243802, "given_name": "Michela", "family_name": "Rimondini", "ORCID": null, "country": null } ], "relevant": false, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2021-03-11T18:45:29Z", "noun_phrases": [ "Insights", "Fostering", "Resilience", "Young Adults", "Multiple Sclerosis", "the Aftermath", "the COVID-19 Emergency", "An Italian Survey" ], "doi": "10.3389/fpsyt.2020.588275", "access": "open", "takeaways": " Recent evidence has demonstrated that the COVID-19 pandemic is taking a toll on the mental health of the general population . The psychological consequences might be even more severe for patients with special healthcare needs and psychological vulnerabilities due to chronic diseases, such as MS .", "categories": [] } ] }